PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
79.31%
Cash & equivalents growing 79.31% while CRVO's declined -83.60%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
79.31%
Below half of CRVO's -83.60%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
70.18%
Below half of CRVO's -30.85%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-6.11%
≥ 1.5x CRVO's -0.00%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.01%
Less than half of CRVO's -75.31%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
-0.83%
1.25-1.5x CRVO's -0.73%. Bruce Berkowitz checks if expansions surpass competitor's pace but remain justified.
No Data
No Data available this quarter, please select a different quarter.
67.39%
Below half of CRVO's -16.45%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-6.24%
Less than half of CRVO's -60.59%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-81.40%
Exceeding 1.5x CRVO's -33.93%. Michael Burry suspects ballooning short-term obligations vs. competitor.
-14.04%
Less than half of CRVO's -36.55%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14.04%
Less than half of CRVO's -32.89%. David Dodd sees far fewer liability expansions relative to competitor.
36.75%
Above 1.5x CRVO's 17.93%. Michael Burry suspects heavy new equity expansion or dilution.
-4.17%
Below half CRVO's 7.45%. Michael Burry suspects major net losses or high dividends vs. competitor.
-5.37%
Higher AOCI Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
105.08%
Below half CRVO's 444.38%. Michael Burry sees potential underperformance in building shareholder capital.
67.39%
Below half CRVO's -16.45%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-79.31%
Less than half of CRVO's 86.64%. David Dodd sees better deleveraging or stronger cash buildup than competitor.